Long Term Follow up Study on a Large Group of Patients with Congenital Factor XIII Deficiency Treated Prophylactically with Fibrogammin P®

Factor XIII deficiency (FXIIID) is an extremely rare hemorrhagic disorder with a prevalence of 1/3-5 million. Management of disease is performed by fresh frozen plasma (FFP), Cryoprecipitate (CP) or FXIII concentrate (Fibrogammin P®). Our objective was to assess safety and effectiveness of Fibrogamm...

Descripción completa

Detalles Bibliográficos
Autores principales: Naderi, Majid, Karimi, Mehran, Hosseini, Maryam Sadat, Moradi, Es′hagh, Shamsizadeh, Morteza, Dorgalaleh, Akbar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Shaheed Beheshti University of Medical Sciences 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5018293/
https://www.ncbi.nlm.nih.gov/pubmed/27642336

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5018293/
https://www.ncbi.nlm.nih.gov/pubmed/27642336

Ejemplares similares